Pykus Therapeutics

Pykus Therapeutics is honored to participate at the European Society of Retina Specialists (EURETINA) Special Focus Meeting OCULAR ENDOTAMPONADES in Athens on Sat 15-Mar 2025. In one of the scientific sessions Friedrich Asmus, MD, will present "Principles and Clinical Pilot Data" of our Investigational Retinal Hydrogel Sealant PYK-2101. We are looking very much forward to a lively exchange with the international retinal surgeon community in Athens. Link to the press release: https://lnkd.in/eD44rJ3R Link to the meeting program: https://lnkd.in/eyJGNeyP #EuretinaSpecialFocus #OcularEndotamponades #RetinaInnovation #EURETINA #RetinaSurgery #Ophthalmology #FightBlindness #seebetterlivebetter #MedTech #RetinaRedefined #RetinalDetachment #Innovation #SeeBrilliantly #HealthcareInnovation #VisionCare #CambridgeMA #MassGeneralBrigham

Pykus Therapeutics expands the patent portfolio for PYK-2101, our First-in-class Retinal Sealant Technology for rapid visual recovery, enhanced outcomes, and a dramatically improved post-operative experience for patients with retinal detachment. The newly issued patent further strengthens Pykus’ global intellectual property portfolio of more than a dozen! issued and pending patents through 2044. Read the full press release here: https://lnkd.in/ej6phEDs Learn more about how the investigational biodegradable hydrogel sealant PYK-2101 works: https://lnkd.in/exJM3k5Q #RetinaSurgery #Ophthalmology #FightBlindness #seebetterlivebetter #MedTech #RetinaRedefined #RetinalDetachment #Innovation #SeeBrilliantly #HealthcareInnovation #VisionCare #CambridgeMA #MassGeneralBrigham

Pykus Therapeutics expands the patent portfolio for PYK-2101, our First-in-class Retinal Sealant Technology for rapid visual recovery, enhanced outcomes, and a dramatically improved post-operative experience for patients with retinal detachment. The newly issued patent further strengthens Pykus’ global intellectual property portfolio of more than a dozen! issued and pending patents through 2044. Read the full press release here: https://lnkd.in/ej6phEDs Learn more about how the investigational biodegradable hydrogel sealant PYK-2101 works: https://lnkd.in/exJM3k5Q #RetinaSurgery #Ophthalmology #FightBlindness #seebetterlivebetter #MedTech #RetinaRedefined #RetinalDetachment #Innovation #SeeBrilliantly #HealthcareInnovation #VisionCare #CambridgeMA #MassGeneralBrigham

Pykus Therapeutics expands the patent portfolio for PYK-2101, our First-in-class Retinal Sealant Technology for rapid visual recovery, enhanced outcomes, and a dramatically improved post-operative experience for patients with retinal detachment. The newly issued patent further strengthens Pykus’ global intellectual property portfolio of more than a dozen! issued and pending patents through 2044. Read the full press release here: https://lnkd.in/ej6phEDs Learn more about how the investigational biodegradable hydrogel sealant PYK-2101 works: https://lnkd.in/exJM3k5Q #RetinaSurgery #Ophthalmology #FightBlindness #seebetterlivebetter #MedTech #RetinaRedefined #RetinalDetachment #Innovation #SeeBrilliantly #HealthcareInnovation #VisionCare #CambridgeMA #MassGeneralBrigham

Pykus Therapeutics is presenting initial clinical data on PYK-2101, our novel retinal sealant, at the #VailVitrectomy 2025 Meeting! PYK-2101 aims to revolutionize retinal detachment surgery - sealing breaks without gas or oil, preserving and accelerating vision recovery, eliminating face-down recovery, and improving outcomes. ?? Presented by: Dr. James (Tony) Stefater, MD, PhD ?? February 10, 2025 | 6:30 AM MST A huge thank you to our incredible team, clinical investigators, and most importantly, the patients who make this research possible! Read the full announcement here: https://lnkd.in/e2PgxTk6 #RetinaSurgery #Ophthalmology #FightBlindness #seebetterlivebetter #MedTech #RetinaRedefined #RetinalDetachment #Innovation #SeeBrilliantly #HealthcareInnovation #VisionCare #CambridgeMA #MassGeneralBrigham